Bill Gates visits KEMRI, pledges continued support for research

American business magnet and philanthropist, Bill Gates visited the Kenya Medical Research Institute (KEMRI) and held discussions with some of the country’s leading research scientists and innovators.
During his three-hours visit at Headquarters on Wednesday, November, 16 2022, Gates, the Founder of the multinational technology corporation, the Microsoft Corporation had a brief consultative meeting Director General Prof. Sam Kariuki and members of the top management.
KEMRI is one of the recipient of collaborative research funding from The Gates Foundation for close to two decades that has resulted in cutting-edge and impactful research findings of global influence to health policies and bettered health systems.
Gates was taken through a number of research projects on Maternal and Child Health including the Child Health and Mortality Prevention Surveillance (CHAMPS), Pregnancy Risk Surveillance Innovation and Measurement Alliance (PRiSMA) and Childhood Acute Illness and Nutrition Network (CHAIN) which are collaborative projects between KEMRI, Ministry of Health and Centre for Disease Research (CDC), Phillips Kenya, the University of Washington, Wellcome Trust and University of Oxford respectively.
He joined a meeting to review the process and results of the CHAMPS and PRiSMA projects being implemented in Western Kenya region of the Kenya.
CHAMPS aims to develop a long-term network of high-quality sites to collect robust and standardized longitudinal data with the overarching objective of understanding and tracking the preventable causes of childhood death globally.
PRiSMA on the other hand is a longitudinal study of maternal and newborn health, with an emphasis on the pregnancy risk factors and their associations with adverse pregnancy outcomes.
CHAIN is a Network of clinical, laboratory, social science and policy researchers who aim to reduce mortality among children being treated for acute illness. With funding from the Bill & Melinda Gates Foundation (BMGF), we established partnerships across Africa and South Asia and a headquarters in Nairobi.
CHAIN is the first of the large BMGF-funded to be coordinated outside the USA.
The first main activity was an international cohort study to examine clinical and social risks and pathways defining mortality risks among young children admitted to hospital and treated according to current guidelines to identify what new interventions may be needed.
Sites were selected to encompass a broad range of settings, populations, hospital types and prevalence of HIV and malaria:
Besides running three sites, the Kenya CHAIN team undertook negotiations with external sites, training, monitored sites, data management and monetary management. The team conducted the main epidemiological, social science and laboratory analyses (KEMRI-UW, KEMRI-WTRP, CMR, CCR) for the cohort.
CHAIN cohort and social science papers have been published.
Microbiome work in CHAIN has made a substantial contribution to the development of an upcoming probiotic product trial involving Bifidobacterium infantis for underweight sponsored by the Gates Medical Research Institute.
Dr James Njunge, a postdoctoral scientist in Kilifi presented this work along with Dr Benson Singa who presented the clinical aspects of such a trial in Kenya.
Ends